Rhodia Targets GMP Manufacturing.

Chemical Market Reporter, August, 1999 by MILMO, SEAN

RHODIA IS PLANNING a fivefold increase in its sales of pharmaceutical intermediates made to current Good Manufacturing Practice (GMP) standards during the next five years. Last year, the company acquired its first cGMP plant, a facility in Holmes Court, northwest England, owned by its parent Rhone-Poulenc.

Rhodia is now on the verge of taking over another cGMP plant from Rhone-Poulenc, at Dagenham, east London. Rhodia also has a small unit at Avonmouth, southwest England, making the pharmaceutical intermediate isoflurane. The company says the UK will become its main base for cGMP production. "We have already started making, at Holmes Court, an active ingredient for a large pharmaceutical company," says Jean-Claude Bravard, president of Rhodia's...

Read the rest of this article with a Free Trial at HighBeam Research.

Premium Content Partnership | HighBeam Research provides an in-depth online archive library of reference works.